NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Quantum BioPharma Ltd. (QNTM) Stock Analysis

Quantum BioPharma Ltd. (QNTM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

QNTM

$3.24

+$0.29 (+9.83%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare QNTM with… →

QNTM Key Statistics

As of Sep 4, 2026
Trading
Open
$3.01
Previous Close
$2.95
Day's Range
2.99–3.27
52-Week Range
2.07–21.00
Volume
110.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.46
Valuation
Market Cap
$20.83M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.89
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$26.18M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
6.43M
1-Year Return
−77.33%
Dividend and dates
Avg Volume
185.78K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

QNTM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−55.62%
2025+98.37%
2024−93.85%
2023+16.75%
2022−22.75%
2021−34.62%
2020−71.27%
2019−87.38%
2018 (partial year)+148.84%

As of September 4, 2026.

QNTM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$26.18M—
2024$0.00−$14.20M—
2023$0.00−$17.90M—
2022$0.00−$23.61M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$15.32M−$26.18M—
2024$0.00—−$15.88M−$14.20M—
2023$0.00—−$19.57M−$17.90M—
2022$0.00—−$27.43M−$23.61M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

QNTM Valuation vs Biotechnology Median

Median of 656 stocks
MetricQNTMBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Quantum BioPharma Ltd. (QNTM) at $20.83M. It is classified in the Biotechnology industry, within the Healthcare sector.

Over the past 52 weeks the price has ranged from $2.07 to $21.00. The most recent close on file for QNTM is $3.24, dated September 4, 2026. That is +$0.29 (+9.83%) against the previous close. The latest close sits 56.52% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $26.18M. Profit margin runs at 0%. Trailing earnings per share are −4.89.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned −77.33%. Across 5 years the annualized return works out at −51.25%. The reported beta is 0.46. Daily returns over the trailing 8 years annualize to a volatility of 138.21%.

Growth & Income

No dividend is on file for QNTM.

Across the complete calendar years on file, 2025 returned +98.37% and 2024 returned −93.85%. Of the 7 complete calendar years on file, 2 finished higher. So far in 2026 the price is −55.62%.

Peer Comparison

Quantum BioPharma Ltd. (QNTM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Quantum BioPharma Ltd. QNTM $20.83M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Quantum BioPharma Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Quantum BioPharma Ltd.

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.

Visit website →